查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1372904

遗传检测市场，2028-全球产业规模、份额、趋势、机会和预测，2018-2028 按疾病类型、技术、地区、竞争细分。

Hereditary Testing Market, 2028- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Disease Type, By Technology, By Region, By Competition.
出版日期: | 出版商: TechSci Research | 英文 173 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球遗传检测市场价值为62.7 亿美元，预计在预测期内将出现令人印象深刻的成长，到2028 年复合年增长率为7.68%。全球遗传检测市场近年来增长显着，彻底改变了我们的检测方式。了解和管理遗传健康。随着基因组学和生物技术的不断进步，遗传检测已成为诊断、治疗和预防各种遗传疾病不可或缺的工具。

遗传检测，也称为基因检测或 DNA 检测，涉及对个体 DNA 的分析，以识别可能与遗传性疾病或病症相关的变化或突变。遗传检测可以帮助诊断遗传性疾病，例如囊性纤维化、亨廷顿舞蹈症和某些类型的癌症。早期诊断有助于更好的疾病管理和个人化治疗计划。个人可以确定他们是否携带可以遗传给后代的基因突变，从而做出明智的计划生育决定。基因测试可以确定个体的基因如何影响他们对特定药物的反应，帮助医疗保健提供者开出最有效和安全的治疗方法。许多人使用遗传测试来追踪他们的祖先并更多地了解他们的遗传遗产。

DNA 定序技术的进步，例如下一代定序 (NGS)，使基因检测变得更容易获得且负担得起，从而扩大了其在医疗保健领域的应用。人们对遗传疾病及其遗传性质的认识不断增强，导致对检测的需求增加，尤其是高风险族群。遗传检测在个人化医疗的发展中发挥着至关重要的作用，可以根据个人的遗传特征量身定制治疗以获得更好的结果。 23andMe 和 AncestryDNA 等公司提供的直接面向消费者的基因检测服务，使基因检测向公众开放，推动了市场成长。政府法规和指导方针有助于确保基因检测服务的品质和准确性，并增强消费者的信心。

市场概况
预测期 2024-2028
2022 年市场规模 62.7亿美元
2028 年市场规模 97.3亿美元
2023-2028 年复合年增长率 7.63%
成长最快的细分市场 遗传性癌症检测
最大的市场 北美洲

主要市场驱动因素

遗传性疾病盛行率的增加正在推动全球遗传检测市场

遗传学领域的进步彻底改变了医疗保健，使一系列疾病的早期诊断和个人化治疗成为可能。这项进展的一个关键方面是遗传检测，它在识别遗传性疾病和评估个人风险因素方面发挥关键作用。由于遗传性疾病盛行率不断增加，全球遗传检测市场正在显着成长。

对个人化医疗的认识和需求不断提高正在推动全球遗传检测市场

近年来，随着个人化医疗的出现，医疗保健领域发生了显着的转变。这种创新方法根据每位患者的个别特征，考虑他们的基因组成、生活方式和环境因素，量身定制治疗方案。遗传检测是个人化医疗的重要组成部分，因其提供了对个别疾病遗传易感性的宝贵见解而受到重视。人们对个人化医疗益处的认识不断增强，以及对客製化医疗保健解决方案的需求推动了全球遗传检测市场的快速扩张。人们对个人化医疗彻底改变医疗保健潜力的认识不断提高，导致遗传检测的需求激增。患者和医疗保健提供者都越来越意识到根据个人基因构成客製化医疗干预措施的重要性，从而提高了基因检测服务的采用率。基因组研究的不断进步扩大了我们对各种疾病遗传基础的理解，包括癌症、心血管疾病和神经退化性疾病。随着研究人员发现更多与这些疾病相关的遗传标记，对评估个人风险的遗传检测的需求不断增加。

向预防性医疗保健的转变是遗传检测需求不断增长的另一个驱动力。许多人现在积极寻求基因检测，以及早发现潜在的健康风险，使他们能够改变生活方式或寻求适当的医疗干预措施来减轻这些风险。遗传检测在计划生育和生殖健康中发挥着至关重要的作用。携带某些遗传性疾病遗传倾向的夫妻可以使用基因检测来评估将这些疾病遗传给孩子的风险。这些知识使他们能够就计划生育做出明智的决定，例如考虑体外受精 (IVF) 和植入前遗传学诊断 (PGD) 等选择。製药和生物技术产业越来越多地利用遗传资讯来开发标靶疗法和药物。这导致对遗传测试的更大需求，以确定这些精准药物的合适候选者，进一步推动市场成长。

主要市场挑战

道德和隐私问题

基因检测市场最突出的挑战之一是与遗传资料的收集、储存和共享相关的道德和隐私问题。遗传讯息是非常个人化的，个人常常担心他们的资料将如何被使用。对资料外洩、基因资讯滥用以及保险公司或雇主歧视的可能性的担忧导致对严格资料保护法规的需求不断增长。

可及性和可负担性

儘管基因检测的成本多年来已显着下降，但它仍然是许多个人和社区的障碍。基因检测并不普及，医疗基础设施的差异可能使边缘化人群处于不利地位。确保公平地获得遗传检测是该行业必须解决的紧迫挑战。

缺乏遗传咨询师

基因测试结果的解释是一个复杂的过程，通常需要遗传咨询师的专业知识。然而，遗传咨询师短缺，特别是在某些地区，这可能会导致结果解释延迟或不准确。该行业需要投资于培训和扩大遗传咨询人员队伍，以满足对其服务不断增长的需求。

临床实用性与解释

基因检测的临床效用是一个关键问题。虽然基因组学的进步导致发现了许多与疾病相关的遗传变异，但其中许多变异的功能意义仍不清楚。临床医生可能很难解释结果并确定其临床相关性，这可能会影响患者护理的品质。

监管和标准化

遗传检测市场是一个快速发展的领域，世界各地的监管机构正在努力製定基因检测的指南和标准。在这个动态环境中实现协调和共识可能具有挑战性。在这一领域运营的公司必须应对复杂的法规网络，各个地区的法规可能存在很大差异。

资料管理和储存

该行业产生的大量遗传资料对资料管理和储存提出了重大挑战。遗传资讯必须安全存储，提供者必须拥有强大的系统来管理和保护这些敏感资料。此外，随着越来越多的人接受基因检测，对高效能资料储存解决方案的需求持续成长。

知情同意和遗传素养

获得基因检测的知情同意至关重要，但确保个人充分理解基因检测的影响可能具有挑战性。无论是医疗保健专业人员或一般大众，基因素养仍然是一个障碍。解决这个问题需要有效的沟通和教育工作。

主要市场趋势

技术进步

在一个以令人难以置信的技术进步为标誌的时代，医疗保健行业正在经历重大变革。遗传检测是一个取得显着进展的领域，由于尖端技术的整合，这一领域出现了前所未有的成长。全球遗传检测市场正在快速扩张，并且没有放缓的迹象。

下一代定序 (NGS) 技术的发展改变了遗传检测的游戏规则。 NGS 可以对个体的整个基因组或特定遗传区域进行快速且经济有效的定序。这扩大了基因检测的范围，能够检测罕见的基因突变，并为个人的遗传倾向提供更全面的见解。大资料和先进生物资讯学工具的涌入彻底改变了遗传资讯的解释。研究人员和医疗保健提供者现在可以分析大量资料集，以识别模式、相关性和潜在的疾病标记物，从而实现更准确的诊断和治疗策略。革命性的 CRISPR-Cas9 基因编辑技术不仅改变了基因研究，而且有望纠正遗传缺陷。这对遗传检测具有深远的影响，因为它可能有助于开发针对个体特定基因突变的基因疗法。直接面向消费者（DTC）的基因检测公司的兴起使得遗传检测更容易为大众所接受。这些公司提供 DNA 检测试剂盒，个人可以在家中使用这些试剂盒来了解他们的血统、健康风险和遗传特征。这种可近性推动了消费者遗传学市场的成长。远距医疗和远距遗传咨询的进步使个人更容易获得基因检测服务并接受遗传咨询师的专家指导，而无需亲自预约。这扩大了遗传检测服务的范围。

细分市场洞察

疾病类型见解

根据疾病类型，遗传性非癌症检测领域将在 2022 年成为全球遗传性检测市场的主导者。遗传性非癌症检测涵盖癌症易感性之外的广泛遗传性疾病。这包括心血管疾病、神经退化性疾病、罕见遗传疾病等疾病的测试。遗传性非癌症检测的更广泛应用使其与更多人群相关，从而导致更高的需求。许多遗传性疾病和癌症无关，但可以显着影响个人的健康和福祉。例子包括囊性纤维化、亨丁顿舞蹈症、肌肉营养不良症等。这些非癌症遗传疾病在人群中的流行增加了对遗传性非癌症检测的需求。对于想要评估将遗传性疾病遗传给后代的风险的个人和夫妻来说，非癌症疾病的基因检测至关重要。此类测试在计划生育和生殖决策中发挥着至关重要的作用。遗传性非癌症检测可以为个人及其医疗保健提供者提供重要的诊断和预后资讯。它可以帮助确定某些健康状况的遗传基础，从而实现个人化的治疗和管理计划。

技术洞察

预计分子测试领域将在预测期内经历快速成长。 DNA 定序、PCR（聚合酶炼式反应）和 SNP（单核苷酸多态性）分析等分子检测技术可在识别与遗传性疾病相关的遗传变异和突变方面提供高精度和准确度。在诊断和预测遗传性疾病的风险时，这种精确度至关重要。分子测试可以对个体的遗传物质进行全面分析。这包括检查整个基因组或与遗传性疾病相关的特定基因。这种综合方法可以更全面地了解个体的遗传风险因子。近年来，分子测试领域取得了重大的技术进展。新一代定序 (NGS) 和先进的 PCR 技术变得更容易取得且更具成本效益。这些创新使得大规模基因检测变得更加容易，从而奠定了该领域的主导地位。分子检测是个人化医疗的基石，可根据个人的基因组成客製化医疗治疗和介入措施。随着个人化医疗的日益普及，分子测试在识别可指导治疗决策和改善患者预后的遗传标记方面变得越来越重要。透过分子技术进行的遗传测试的范围不断扩大。这些测试涵盖多种疾病，包括癌症易感性、心血管疾病、罕见遗传性疾病等。分子检测的多功能性吸引了广大医疗保健提供者和患者。分子检测通常伴随着遗传咨询服务。遗传咨询师在解释测试结果、解释其对患者的影响以及帮助他们做出有关医疗保健的明智决定方面发挥着至关重要的作用。这种整合增加了分子测试服务的价值。

区域洞察

2022年，欧洲成为全球遗传检测市场的主导者，以价值计算，占据最大的市场份额。欧洲拥有高度发展的医疗保健基础设施，可以使用最先进的医疗设施和熟练的医疗保健专业人员。该基础设施支持先进医疗技术的采用和发展，包括遗传检测。欧洲拥有完善的医疗保健和医疗器材监管框架，确保遗传检测产品和服务符合高品质标准并遵守道德准则。这种监管环境为医疗保健提供者和患者註入了信心。许多欧洲国家在生物医学研究和基因组学方面处于领先地位。他们在研发方面投入巨资，从而开发出创新的遗传检测方法、技术和治疗方法。这增强了在全球市场的竞争优势。欧洲国家通常也将国内生产毛额的很大一部分分配给医疗保健。这项巨额投资使包括基因检测在内的先进医疗技术得以广泛采用，并确保大部分人口能够获得这些技术。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球遗传检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型（遗传性癌症检测、遗传性非癌症检测）
    • 依技术（细胞遗传学、生化、分子检测）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图

第 6 章：北美遗传检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型
    • 依技术
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲遗传检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型
    • 依技术
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区基因检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型
    • 依技术
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲遗传检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型
    • 依技术
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲遗传检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型
    • 依技术
  • MEA：国家分析
    • 南非遗传检测
    • 沙乌地阿拉伯遗传检测
    • 阿联酋遗传检测

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 併购
  • 产品开发
  • 最近的发展

第 13 章：全球遗传检测市场：SWOT 分析

第14章：竞争格局

  • 商业概览
  • 应用程式产品
  • 最近的发展
  • 主要人员
  • SWOT分析
    • Myriad Genetics, Inc.
    • Illumina, Inc.
    • Natera, Inc.
    • Laboratory Corporation of America Holdings
    • F. Hoffmann-La Roche Ltd.
    • Quest Diagnostics Incorporated
    • COOPERSURGICAL, INC.
    • Agilent Technologies, Inc.
    • Thermo Fisher Scientific, Inc.
    • SOPHiA GENETICS

第 15 章：策略建议

第 16 章：关于我们与免责声明

简介目录
Product Code: 16282

The Global Hereditary Testing Market has valued at USD 6.27 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.68% through 2028. The global hereditary testing market has witnessed remarkable growth in recent years, revolutionizing the way we understand and manage genetic health. As advances in genomics and biotechnology continue to accelerate, hereditary testing has become an indispensable tool in diagnosing, treating, and preventing a wide range of genetic conditions.

Hereditary testing, also known as genetic testing or DNA testing, involves the analysis of an individual's DNA to identify changes or mutations that may be associated with inherited diseases or conditions. Hereditary testing can help diagnose genetic disorders, such as cystic fibrosis, Huntington's disease, and certain types of cancer. Early diagnosis allows for better disease management and personalized treatment plans. Individuals can determine if they carry gene mutations that could be passed on to their offspring, enabling informed family planning decisions. Genetic testing can identify how an individual's genes may influence their response to specific medications, helping healthcare providers prescribe the most effective and safe treatments. Many people use hereditary testing to trace their ancestry and learn more about their genetic heritage.

Advances in DNA sequencing technologies, such as next-generation sequencing (NGS), have made genetic testing more accessible and affordable, expanding its use in healthcare. Growing awareness of genetic diseases and their hereditary nature has led to increased demand for testing, especially among at-risk populations. Hereditary testing plays a crucial role in the development of personalized medicine, tailoring treatments to an individual's genetic profile for better outcomes. Direct-to-consumer genetic testing services, offered by companies like 23andMe and AncestryDNA, have made genetic testing accessible to the general public, driving market growth. Government regulations and guidelines have helped ensure the quality and accuracy of genetic testing services, boosting consumer confidence.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 6.27 Billion
Market Size 2028USD 9.73 Billion
CAGR 2023-20287.63%
Fastest Growing SegmentHereditary Cancer Testing
Largest MarketNorth America

Key Market Drivers

Increasing Prevalence of Genetic Disorders is Driving Global Hereditary Testing Market

Advancements in the field of genetics have revolutionized healthcare, enabling early diagnosis and personalized treatment for a range of diseases. One crucial aspect of this progress is hereditary testing, which plays a pivotal role in identifying genetic disorders and assessing an individual's risk factors. The global hereditary testing market is witnessing remarkable growth due to the increasing prevalence of genetic disorders.

The prevalence of genetic disorders has been on the rise, prompting an increased demand for hereditary testing. Several factors contribute to this growing prevalence. As the global population ages, the risk of genetic disorders increases. Many genetic conditions are more likely to manifest as individuals get older, necessitating early detection and intervention. Ongoing research has led to the discovery of new genetic markers and associations with diseases. This expanded knowledge has prompted healthcare providers to recommend hereditary testing for a wider range of conditions. Couples planning to have children are increasingly opting for carrier testing to determine if they carry genetic mutations that could be passed on to their offspring. This proactive approach helps in making informed reproductive decisions. Hereditary testing is being utilized to assess an individual's susceptibility to hereditary cancers such as breast, ovarian, and colon cancer. This empowers individuals to take preventive measures and undergo more frequent screenings.

Rising Awareness and Demand for Personalized Medicine is Driving Global Hereditary Testing Market

In recent years, the field of healthcare has witnessed a remarkable transformation with the advent of personalized medicine. This innovative approach tailors medical treatments to the individual characteristics of each patient, considering their genetic makeup, lifestyle, and environmental factors. Hereditary testing, a critical component of personalized medicine, has gained significant prominence as it provides invaluable insights into an individual's genetic predisposition to diseases. The growing awareness of personalized medicine's benefits and the demand for tailored healthcare solutions have fueled the rapid expansion of the global hereditary testing market. Increased awareness of personalized medicine's potential to revolutionize healthcare has led to a surge in demand for hereditary testing. Patients and healthcare providers alike are becoming more conscious of the importance of tailoring medical interventions to an individual's genetic makeup, resulting in a higher adoption rate for genetic testing services. Ongoing advancements in genomic research have expanded our understanding of the genetic basis of various diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions. As researchers uncover more genetic markers associated with these diseases, the demand for hereditary testing to assess an individual's risk escalates.

The shift towards preventive healthcare is another driving force behind the increasing demand for hereditary testing. Many individuals are now proactively seeking genetic testing to identify potential health risks early on, allowing them to make lifestyle modifications or seek appropriate medical interventions to mitigate those risks. Hereditary testing plays a crucial role in family planning and reproductive health. Couples who carry a genetic predisposition to certain inherited diseases can use genetic testing to assess their risk of passing these conditions to their children. This knowledge enables them to make informed decisions about family planning, such as considering options like in vitro fertilization (IVF) with preimplantation genetic diagnosis (PGD). The pharmaceutical and biotech industries are increasingly utilizing genetic information to develop targeted therapies and drugs. This has led to a greater need for hereditary testing to identify suitable candidates for these precision medicines, further driving market growth.

Key Market Challenges

Ethical and Privacy Concerns

One of the most prominent challenges in the hereditary testing market revolves around the ethical and privacy concerns associated with the collection, storage, and sharing of genetic data. Genetic information is intensely personal, and individuals are often apprehensive about how their data will be used. Concerns over data breaches, misuse of genetic information, and the potential for discrimination by insurers or employers have led to a growing demand for stringent data protection regulations.

Accessibility and Affordability

While the cost of genetic testing has significantly decreased over the years, it remains a barrier for many individuals and communities. Access to genetic testing is not universal, and disparities in healthcare infrastructure can leave marginalized populations at a disadvantage. Ensuring equitable access to hereditary testing is a pressing challenge that the industry must address.

Lack of Genetic Counselors

The interpretation of genetic test results is a complex process that often requires the expertise of genetic counselors. However, there is a shortage of genetic counselors, particularly in some regions, which can result in delayed or inaccurate interpretation of results. The industry needs to invest in training and expanding the genetic counseling workforce to meet the growing demand for their services.

Clinical Utility and Interpretation

The clinical utility of genetic testing is a critical concern. While advancements in genomics have led to the discovery of numerous genetic variants associated with diseases, the functional significance of many of these variants remains unclear. Clinicians may struggle to interpret results and determine their clinical relevance, which can impact the quality of patient care.

Regulation and Standardization

The hereditary testing market is a rapidly evolving field, and regulatory bodies worldwide are working to establish guidelines and standards for genetic testing. Achieving harmonization and consensus in this dynamic environment can be challenging. Companies operating in this space must navigate a complex web of regulations, which can vary significantly from one region to another.

Data Management and Storage

The sheer volume of genetic data generated by the industry presents a significant challenge in terms of data management and storage. Genetic information must be stored securely, and providers must have robust systems in place to manage and protect this sensitive data. Moreover, as more individuals undergo genetic testing, the demand for efficient data storage solutions continues to grow.

Informed Consent and Genetic Literacy

Obtaining informed consent for genetic testing is crucial, but ensuring individuals fully understand the implications of genetic testing can be challenging. Genetic literacy, both among healthcare professionals and the general public, remains a hurdle. Effective communication and education efforts are necessary to address this issue.

Key Market Trends

Technological Advancements

In an era marked by incredible technological advancements, the healthcare industry is undergoing a significant transformation. One area that has seen remarkable progress is hereditary testing, a field that has witnessed unprecedented growth due to the integration of cutting-edge technologies. The global hereditary testing market is expanding at a rapid pace, and it shows no signs of slowing down.

The development of Next-Generation Sequencing (NGS) technologies has been a game-changer in hereditary testing. NGS allows for the rapid and cost-effective sequencing of an individual's entire genome or specific genetic regions. This has expanded the scope of genetic testing, enabling the detection of rare genetic mutations and providing more comprehensive insights into an individual's genetic predispositions. The influx of big data and advanced bioinformatics tools has revolutionized the interpretation of genetic information. Researchers and healthcare providers can now analyze vast datasets to identify patterns, correlations, and potential disease markers, leading to more accurate diagnoses and treatment strategies. The revolutionary CRISPR-Cas9 gene-editing technology has not only transformed genetic research but also holds the promise of correcting genetic defects. This has profound implications for hereditary testing, as it may enable the development of gene therapies tailored to an individual's specific genetic mutations. The rise of direct-to-consumer (DTC) genetic testing companies has made hereditary testing more accessible to the general public. These companies offer DNA testing kits that individuals can use at home to learn about their ancestry, health risks, and genetic traits. This accessibility has fueled the growth of the consumer genetics market. Advances in telemedicine and remote genetic counseling have made it easier for individuals to access genetic testing services and receive expert guidance from genetic counselors without the need for in-person appointments. This has broadened the reach of hereditary testing services.

Segmental Insights

Disease Type Insights

Based on the Disease Type, the hereditary non-cancer testing segment emerged as the dominant player in the global market for Hereditary Testing in 2022. Hereditary non-cancer testing encompasses a wide range of genetic conditions beyond cancer predisposition. This includes tests for conditions like cardiovascular diseases, neurodegenerative disorders, rare genetic diseases, and more. The broader application of hereditary non-cancer testing makes it relevant to a larger population, leading to higher demand. Many genetic disorders and diseases have nothing to do with cancer but can significantly impact an individual's health and well-being. Examples include cystic fibrosis, Huntington's disease, muscular dystrophy, and many others. The prevalence of these non-cancer genetic diseases in the population contributes to the demand for hereditary non-cancer testing. Genetic testing for non-cancer conditions is crucial for individuals and couples who want to assess their risk of passing on genetic diseases to their offspring. This type of testing plays a critical role in family planning and reproductive decisions. Hereditary non-cancer testing can provide important diagnostic and prognostic information for individuals and their healthcare providers. It can help identify the genetic basis of certain health conditions, enabling personalized treatment and management plans.

Technology Insights

The molecular testing segment is projected to experience rapid growth during the forecast period. Molecular testing techniques, such as DNA sequencing, PCR (Polymerase Chain Reaction), and SNP (Single Nucleotide Polymorphism) analysis, offer high precision and accuracy in identifying genetic variations and mutations associated with hereditary diseases. This precision is crucial when it comes to diagnosing and predicting the risk of genetic disorders. Molecular testing allows for comprehensive analysis of an individual's genetic material. This includes the examination of the entire genome or specific genes associated with hereditary conditions. This comprehensive approach provides a more thorough understanding of an individual's genetic risk factors. The field of molecular testing has seen significant technological advancements in recent years. Next-generation sequencing (NGS) and advanced PCR techniques have become more accessible and cost-effective. These innovations have made it easier to conduct large-scale genetic testing, contributing to the segment's dominance. Molecular testing is a cornerstone of personalized medicine, which tailors medical treatments and interventions to an individual's genetic makeup. As personalized medicine gains prominence, molecular testing becomes increasingly important in identifying genetic markers that can guide treatment decisions and improve patient outcomes. The range of hereditary tests that can be conducted through molecular techniques continues to expand. These tests cover a wide spectrum of conditions, including cancer predisposition, cardiovascular diseases, rare genetic disorders, and more. The versatility of molecular testing appeals to a broad audience of healthcare providers and patients. Molecular testing is often accompanied by genetic counseling services. Genetic counselors play a crucial role in interpreting test results, explaining their implications to patients, and helping them make informed decisions about their healthcare. This integration adds value to molecular testing services.

Regional Insights

Europe emerged as the dominant player in the global Hereditary Testing market in 2022, holding the largest market share in terms of value. Europe boasts a highly developed healthcare infrastructure with access to state-of-the-art medical facilities and skilled healthcare professionals. This infrastructure supports the adoption and growth of advanced medical technologies, including hereditary testing. Europe has a well-established regulatory framework for healthcare and medical devices, ensuring that hereditary testing products and services meet high-quality standards and adhere to ethical guidelines. This regulatory environment instills confidence in both healthcare providers and patients. Many European countries are leaders in biomedical research and genomics. They invest heavily in research and development, leading to the development of innovative hereditary testing methods, technologies, and treatments. This fosters a competitive advantage in the global market. European countries also generally allocate a significant portion of their GDP to healthcare. This substantial investment enables the widespread adoption of advanced medical technologies, including genetic testing, and ensures access for a large portion of the population.

Key Market Players

  • Myriad Genetics, Inc.
  • Illumina, Inc.
  • Natera, Inc.
  • Laboratory Corporation of America Holdings
  • F. Hoffmann-La Roche Ltd.
  • Quest Diagnostics Incorporated
  • COOPERSURGICAL, INC.
  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific, Inc.
  • SOPHiA GENETICS

Report Scope:

In this report, the Global Hereditary Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hereditary Testing Market, By Disease Type:

  • Hereditary Cancer Testing
  • Hereditary Non-cancer Testing

Hereditary Testing Market, By Technology:

  • Cytogenetic
  • Biochemical
  • Molecular Testing

Hereditary Testing Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Hereditary Testing Market.

Available Customizations:

  • Global Hereditary Testing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

4. Voice of Customer

5. Global Hereditary Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Hereditary Cancer Testing, Hereditary Non-cancer Testing)
    • 5.2.2. By Technology (Cytogenetic, Biochemical, Molecular Testing)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Market Map

6. North America Hereditary Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Technology
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Hereditary Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Technology
    • 6.3.2. Canada Hereditary Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Technology
    • 6.3.3. Mexico Hereditary Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Technology

7. Europe Hereditary Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Technology
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Hereditary Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Technology
    • 7.3.2. United Kingdom Hereditary Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Technology
    • 7.3.3. Italy Hereditary Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Technology
    • 7.3.4. France Hereditary Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Technology
    • 7.3.5. Spain Hereditary Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Technology

8. Asia-Pacific Hereditary Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Technology
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Hereditary Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Technology
    • 8.3.2. India Hereditary Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Technology
    • 8.3.3. Japan Hereditary Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Technology
    • 8.3.4. South Korea Hereditary Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Technology
    • 8.3.5. Australia Hereditary Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Technology

9. South America Hereditary Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Technology
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Hereditary Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Technology
    • 9.3.2. Argentina Hereditary Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Technology
    • 9.3.3. Colombia Hereditary Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Technology

10. Middle East and Africa Hereditary Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Technology
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Hereditary Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Technology
    • 10.3.2. Saudi Arabia Hereditary Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Technology
    • 10.3.3. UAE Hereditary Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Global Hereditary Testing Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Application Offerings
  • 14.3. Recent Developments
  • 14.4. Key Personnel
  • 14.5. SWOT Analysis
    • 14.5.1. Myriad Genetics, Inc.
    • 14.5.2. Illumina, Inc.
    • 14.5.3. Natera, Inc.
    • 14.5.4. Laboratory Corporation of America Holdings
    • 14.5.5. F. Hoffmann-La Roche Ltd.
    • 14.5.6. Quest Diagnostics Incorporated
    • 14.5.7. COOPERSURGICAL, INC.
    • 14.5.8. Agilent Technologies, Inc.
    • 14.5.9. Thermo Fisher Scientific, Inc.
    • 14.5.10. SOPHiA GENETICS

15. Strategic Recommendations

16. About Us & Disclaimer